Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.







26.09.2021

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that starting October 2021, Stephanie Kniep will be heading the company’s Investor Relations (IR) activities. With her vast IR experience and knowledge, she will contribute to Marinomed’s strategic communications and positioning on the international capital markets. Stephanie Kniep is a renowned IR Manager with more than 20 years of experience.
Marinomed Biotech: weekly performance: 0.86%

Valneva: Valneva, an Austrian/French specialty vaccine company, announced that it has commenced recruitment of adolescents in its pivotal Phase 3 Clinical Trial (VLA2001-301, “Cov-Compare”) for its inactivated COVID-19 vaccine candidate VLA2001 in the United Kingdom. Topline results from the pivotal Cov-Compare trial are expected early in the fourth quarter of 2021 and are intended to form the basis for potential regulatory approval in adults. The Company has also started to provide boosters to volunteers in its Phase 1/2 VLA2001-201 trial. This planned expansion of VLA2001 clinical trials will support future approval in further age groups, in addition to adults. Further, the company said it continues discussions with the European Commission regarding a potential VLA2001 supply contract. The Company is also actively pursuing opportunities to make VLA2001 available to other customers, subject to positive Cov-Compare data and regulatory approval. CEO  Thomas Lingelbach commented, “Our teams at Valneva remain fully committed to carry out VLA2001’s development plan and bring our inactivated vaccine to all patient groups who could benefit. We continue to receive messages on a daily basis from people across the world who are waiting for an inactivated vaccine so we continue to believe that our differentiated vaccine candidate could contribute to the ongoing fight against the COVID-19 pandemic. We’re confident that many countries, and regulators, will want to have the opportunity to consider our inactivated COVID-19 vaccine.”  
Valneva: weekly performance: 17.53%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (23/09/2021)


 

Bildnachweis

1. Wir verfügen über eine solide Datenbank zur Sicherheit dieses inaktivierten Virusansatzes. Thomas Lingelbach, CEO Valneva



Aktien auf dem Radar:Strabag.


Random Partner

KTM
Die KTM Industries-Gruppe ist eine europäische Fahrzeug-Gruppe mit dem strategischen Fokus auf das globale Sportmotorradsegment und den automotiven high-tech Komponentenbereich. Mit ihren weltweit bekannten Marken KTM, Husqvarna Motorcycles, WP und Pankl zählt sie in ihren Segmenten jeweils zu den Technologie- und Marktführern.

>> Besuchen Sie 66 weitere Partner auf boerse-social.com/partner



Meistgelesen
>> mehr


PIR-Zeichnungsprodukte
AT0000A20DP5
AT0000A2SAM3
AT0000A26J44

Börse Social Club Board
>> mehr
    #gabb #950